A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

What Is BCG Treatment for Bladder Cancer? Bacillus Calmette-Guérin (BCG) is the main immunotherapy used to treat early-stage bladder cancer. Immunotherapy uses your immune system to fight cancer. BCG ...

Findings from the primary analysis of the phase 3b PATAPSCO study showed that adding durvalumab (Imfinzi) to BCG induction ...

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas. Adding subcutaneous sasanlimab to Bacillus ...

ImmunityBio Inc. IBRX on Monday said it entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ...

If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your options, talk to a urologist or genitourinary oncologist about whether Inlexzo ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...